TD Cowen analyst Ryan Langston lowered the firm’s price target on Astrana Health (ASTH) to $35 from $40 and keeps a Buy rating on the shares. The firm said its forward estimates reflecttheir cautious outlook on Medicaid and the VBC environment.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health Inc. Reports Strong Q3 Earnings Amid Growth
- Astrana Health Reports Strong Revenue Growth in Q3 2025
- Strong Q3 Performance and Strategic Partnerships Justify Buy Rating for Astrana Health
- Astrana Health Reports Strong Q3 Revenue Growth
- Astrana Health reports Q3 EPS 1c vs. 33c last year